Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Targets ALS In Expansion Of Cytokinetics Alliance

Executive Summary

Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.

You may also be interested in...



Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants

In VC deals, Magenta raised $50m, licensed a Novartis asset and engaged an important partner. Seven public companies revealed financial transactions totaling $947.4m, including Achaogen's $20.5m from the Gates Foundation. Also, OncoMed, Regulus and Depomed provided restructuring updates.

Cytokinetics Seeks ALS Success By Focusing On Lung Function

Despite an earlier Phase II failure on broader ALS endpoint, biotech thinks it can demonstrate efficacy in slowing lung-function decline in ALS patients.

Big US Step For Mitsubishi Tanabe As Edaravone Filed For ALS

Japan's Mitsubishi Tanabe has taken an important step forward in the US with an approval filing for what will be its key strategic product in this market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel